Moderna (MRNA) Net Margin (2017 - 2026)

Moderna (MRNA) has 10 years of Net Margin data on file, last reported at 345.24% in Q1 2026.

• On a quarterly basis, Net Margin rose 55383.0% year-over-year to 345.24% in Q1 2026; TTM through Mar 2026 was 143.55%, a 3788.0% decrease from a year earlier, with the FY2025 full-year figure at 145.16%, down 3512.0% from the prior year.
• Net Margin for Q1 2026 stood at 345.24%, down from 121.83% in the prior quarter.
• Over the last five years, Net Margin for MRNA reached as high as 60.29% in Q1 2022 and fell as low as 899.07% in Q1 2025.
• Historically, Net Margin has averaged 219.85% across 5 years, with a median of 115.94% in 2024.
• Across the five-year window, Net Margin tumbled 70784 bps in 2024 and surged 55383 bps in 2026, its largest moves.
• Year by year, Net Margin stood at 28.82% in 2022, then slumped by 73 bps to 7.72% in 2023, then slumped by 1602 bps to 115.94% in 2024, then fell by 5 bps to 121.83% in 2025, then plunged by 183 bps to 345.24% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 345.24% in Q1 2026, 121.83% in Q4 2025, and 19.69% in Q3 2025.